Listeria monocytogenes cholecystitis: a possible new syndrome.

Jackrapong Bruminhent, Timothy K Lynch, Jonathan Gefen, Jerome Santoro

Department of Internal Medicine, Division of Infectious Diseases and Environmental Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA. jbruminhent@gmail.com

The American journal of the medical sciences 2013 May

filter terms:

The U.S. Food and Drug Administration recently added potentially fatal Listeria monocytogenes infection to the list of opportunistic infections that can occur in patients who receive tumor necrosis factor inhibitor therapy. In this study, the first reported case of L monocytogenes cholecystitis associated with etanercept use is described. It also appears that tumor necrosis factor inhibitor therapy likely increases the risk for Listeria cholecystitis. Clinicians need to be aware of this association when selecting antimicrobial therapy for these patients.

Citation

Jackrapong Bruminhent, Timothy K Lynch, Jonathan Gefen, Jerome Santoro. Listeria monocytogenes cholecystitis: a possible new syndrome. The American journal of the medical sciences. 2013 May;345(5):414-7